Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Docirbrutinib (AS-1763), a novel non-COVALENT pan-mutant BTK inhibitor, demonstrates durable clinical responses in patients with previously treated B-cell malignancies: Data from an ongoing Phase 1b study

View Full Paper
Ask AI
Bookmark
Share

Authors

JDJames D’OlimpioAGAndrew Gillis-SmithSMShuo Ma

Discussion

Loading...

Member takes

Overview

Phase 1b trial reveals anti-tumor activities in chronic lymphocytic leukemia patients, indicating promising outcomes with docirbrutinib.

Key Points

  • Docirbrutinib demonstrates anti-tumor activities in patients with chronic lymphocytic leukemia and other B-cell malignancies, along with a favorable safety profile.
  • Overall response rate for chronic lymphocytic leukemia patients reached 50%, with a median treatment duration of 6 months.
  • Ongoing Phase 1b study involves dose escalation and expansion in patients previously treated with other therapies, targeting recommended Phase 2 dosing.
  • Research supports further assessment of docirbrutinib's efficacy, noting no major drug-related complications detected during the trial.

Cite This Study

D’Olimpio et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d860https://doi.org/10.1182/blood-2025-3892
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Final update from the Phase 1/2 BRUIN study2025 · 6 citations
  2. 2Pirtobrutinib vs ibrutinib in treatment-naïve and relapsed/refractory CLL/SLL: Results from the first randomized phase III study comparing a non-covalent and covalent BTK inhibitor2025 · 2 citations
  3. 3Pirtobrutinib, a non-covalent BTK inhibitor, enhances T-cell anti-tumor immunity in chronic lymphocytic leukemia (CLL)2025
  4. 4Updates of R/R CLL with prior exposure to Bruton's tyrosine kinase (BTK) inhibitor and/or bcl-2 inhibitor in the Phase 1 trial of LP-168 (Rocbrutinib), a novel COVALENT and non-COVALENT BTK inhibitor2025 · 2 citations
  5. 5Pirtobrutinib in Relapsed/Refractory (R/R) Waldenström macroglobulinemia (WM): Up to 5 years of follow-up from the Phase 1/2 BRUIN study2025 · 3 citations